These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 18184520

  • 1. Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia--changes in serum potassium levels with or without a RAAS inhibitor.
    Tomino Y, Yamazaki T, Shou I, Tsuge T, Satake K, Takeda Y, Ohtani A, Nishitani T, Kurusu A, Hamada C, Horikoshi S, Maeda K, Tanaka Y, Fukuda H, Wakabayashi M, Seto T.
    Clin Nephrol; 2007 Dec; 68(6):379-85. PubMed ID: 18184520
    [Abstract] [Full Text] [Related]

  • 2. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA, Gales MA.
    Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
    [Abstract] [Full Text] [Related]

  • 3. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators.
    JAMA; 2015 Jul 14; 314(2):151-61. PubMed ID: 26172895
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
    Kloner RA, Gross C, Yuan J, Conrad A, Pergola PE.
    J Cardiovasc Pharmacol Ther; 2018 Nov 14; 23(6):524-531. PubMed ID: 30103622
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia.
    Mistry M, Shea A, Giguère P, Nguyen ML.
    Ann Pharmacother; 2016 Jun 14; 50(6):455-62. PubMed ID: 27048188
    [Abstract] [Full Text] [Related]

  • 7. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators.
    N Engl J Med; 2015 Jan 15; 372(3):211-21. PubMed ID: 25415805
    [Abstract] [Full Text] [Related]

  • 8. Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy.
    Chernin G, Gal-Oz A, Ben-Assa E, Schwartz IF, Weinstein T, Schwartz D, Silverberg DS.
    Clin Cardiol; 2012 Jan 15; 35(1):32-6. PubMed ID: 22057933
    [Abstract] [Full Text] [Related]

  • 9. Calcium-Polystyrene Sulfonate Decreases Inter-Dialytic Hyperkalemia in Patients Undergoing Maintenance Hemodialysis: A Prospective, Randomized, Crossover Study.
    Wang J, Lv MM, Zach O, Wang LY, Zhou MY, Song GR, Zhang X, Lin HL.
    Ther Apher Dial; 2018 Dec 15; 22(6):609-616. PubMed ID: 30109784
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.
    Georgianos PI, Liampas I, Kyriakou A, Vaios V, Raptis V, Savvidis N, Sioulis A, Liakopoulos V, Balaskas EV, Zebekakis PE.
    Int Urol Nephrol; 2017 Dec 15; 49(12):2217-2221. PubMed ID: 29027620
    [Abstract] [Full Text] [Related]

  • 11. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH.
    Kidney Int; 2016 Sep 15; 90(3):696-704. PubMed ID: 27350174
    [Abstract] [Full Text] [Related]

  • 12. Management of hyperkalemia in hospitalized patients.
    Fordjour KN, Walton T, Doran JJ.
    Am J Med Sci; 2014 Feb 15; 347(2):93-100. PubMed ID: 23255245
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF.
    Mayo Clin Proc; 2020 Feb 15; 95(2):339-354. PubMed ID: 31668450
    [Abstract] [Full Text] [Related]

  • 15. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study.
    Hagan AE, Farrington CA, Wall GC, Belz MM.
    Clin Nephrol; 2016 Jan 15; 85(1):38-43. PubMed ID: 26587776
    [Abstract] [Full Text] [Related]

  • 16. Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia.
    Nakayama Y, Ueda K, Yamagishi SI, Sugiyama M, Yoshida C, Kurokawa Y, Nakamura N, Moriyama T, Kodama G, Minezaki T, Ito S, Nagata A, Taguchi K, Yano J, Kaida Y, Shibatomi K, Fukami K.
    Clin Exp Nephrol; 2018 Feb 15; 22(1):35-44. PubMed ID: 28421299
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR, Rolfe M.
    Clin J Am Soc Nephrol; 2010 Mar 15; 5(3):531-48. PubMed ID: 20150448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.